Table 2.
Combination agents of ATP-competitive FAK inhibitor
| FAK inhibitor name |
Combination agents | Cancer Type | In vitro experiments | In vivo experiments | ||
|---|---|---|---|---|---|---|
| Synergistic effects | Reverse resistance | Inhibit growth | Extended survival | |||
|
TAE226 (NVP-226) |
Docetaxel | OC | √ | √ | √ | √ |
| Conventional chemotherapeutic | EWS | √ | ||||
| Nilotinib | Ph+ALL | √ | √ | |||
| (nab-)paclitaxel | PDAC | √ | √ | √ | ||
|
VS-6062 (PF00562271) |
AZD-1152 | EWS | √ | √ | √ | |
| Ganciclovir | GBM | √ | √ | |||
| ABT-737 | OCCC | √ | √ | |||
|
PF-573228 (PF-228) |
Erlotinib | NSCLC | √ | √ | ||
| Lexatumumab | PDAC | √ | √ | √ | ||
| Tamoxifen | ER+BC | √ | ||||
|
VS-6063 (Defactinib) |
Docetaxel | CRPC | √ | √ | ||
| Paclitaxel | OC | √ | √ | √ | √ | |
| Gefitinib | NSCLC | √ | √ | √ | ||
| (nab-)paclitaxel | PDAC | √ | √ | |||
| Everolimus | PanNETs | √ | √ | |||
| GSK2256098 | Gemcitabine | PC | √ | √ | √ | |
| Paclitaxel | Uterine cancer | √ | √ | |||
|
VS-4718 (PND-1186) |
ABT-199 | AML | √ | |||
| Bortezomib& Carfilzomib | MM | √ | √ | √ | √ | |
| Dasatinib | Ph + ALL | √ | √ | √ | ||
OC ovarian cancer, EWS Ewing’s sarcoma, Ph+ALL Ph+acute lymphoblastic leukemia, PDAC pancreatic ductal adenocarcinoma, GBM glioblastoma multiforme, OCCC ovarian clear cell carcinoma, NSCLC non-small cell lung cancer, ER+BC ER+breast cancer, CRPC castration-resistant prostate cancer, PanNETs pancreatic neuroendocrine tumors, PC pancreatic cancer, AML acute myeloid leukemia, MM multiple myeloma